Compare Array Biopharma vs Exelixis
Customers evaluate the quality of Array Biopharma's products using the following success metrics.
Overview
Array Biopharma is 26 yrs old and is based in United States.
Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. The company is building a fully integrated, commercial-stage biopharmaceutical company that discovers, develops and markets safe and effective small molecule drugs to treat patients afflicted with cancer.
Exelixis is 30 yrs old and is based in United States.
Exelixis (NASDAQ: EXEL) is a development-stage biotechnology company dedicated to the discovery and development of small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer.
Demo Video
Leadership
Kyle Lefkoff (Founder)
Stelios B. Papadopoulos (Founder)
Investors
Pfizer, Frazier Healthcare Partners
Domain Associates, Pappas Ventures
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Array Biopharma has not claimed their profile.
Work for Array Biopharma? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Array Biopharma?
Claim your profile now.
Information not available because Exelixis has not claimed their profile.
Work for Exelixis? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Exelixis?
Claim your profile now.